FANGZHOU JIANKE (06086), a leader in "AI + chronic disease management," has achieved a milestone with its self-developed AI superbrain—the "XingJie AI Model"—successfully completing generative AI service filing (Filing No.: Guangdong-XingJie-202509120089) with the Cyberspace Administration of China. On October 31, the "Filing Empowerment, Guangdong Innovation" provincial AI model launch event (Phase 1) was held in Shenzhen, where FANGZHOU JIANKE received the "Generative AI Service Filing Certificate."
Dr. Xie Fangmin, Founder, Chairman, and CEO of FANGZHOU JIANKE, emphasized during the event that the XingJie AI Model represents a significant advancement in the company’s AI-driven chronic disease management efforts. "True AI empowerment is not about stacking features but making healthcare proactive, predictive, and omnipresent," he stated. Leveraging this breakthrough, FANGZHOU JIANKE aims to expand its AI+H2H (Hospital To Home) ecosystem, integrating cutting-edge AI with professional medical services to deliver smarter, more personalized care.
The national filing marks a shift from traditional reactive Q&A services to AI-powered proactive insights and tailored solutions in chronic disease management. Notably, FANGZHOU JIANKE stands out as one of the few internet healthcare firms with dual-model capabilities, combining the XingJie AI Model and the XingShi Medical AI Model to solidify its technological edge.
**Three Innovation Pillars Strengthen AI+H2H Foundation** Addressing growing complexities in chronic disease management—such as limited access to consultations, medication procurement challenges, and poor adherence—the XingJie AI Model is designed as a "partner" that deeply understands user needs. Its core strengths rest on three pillars: 1. **Technological Breakthroughs**: Advanced emotional perception and intent reasoning enable preemptive responses, while its smart hub dynamically allocates resources for optimal speed and accuracy. 2. **Application Innovation**: Transitioning from app-based interactions to AI-driven assistants, the model enhances user experience via multimodal technology and proactive task execution, alleviating resource bottlenecks. 3. **Operational Efficiency**: A self-evolving knowledge base reduces maintenance costs by autonomously updating medical and enterprise data, extending services across entire business chains.
**Dual-Model Ecosystem Unleashes Value** With the XingJie AI Model as its "foundation" and the XingShi Medical AI Model as the "wheel," FANGZHOU JIANKE is advancing its AI ecosystem. Strategic partnerships with global pharmaceutical leaders like Novo Nordisk, Innovent Biologics, and Fosun Pharma aim to establish AI-powered disease management benchmarks, transitioning the industry from empirical to systematic, intelligent services. Recent successes include closed-loop AI solutions for weight management (e.g., personalized plans and 24/7 medication guidance) and psoriasis (spanning education, intervention, and follow-up).
**Aligning with National "AI+" Initiatives** FANGZHOU JIANKE’s efforts resonate with China’s "AI+" action plan, which promotes AI integration across industries, and the National Health Commission’s guidelines on multi-disease chronic care and digital empowerment. Moving forward, the company will deepen R&D in AI applications for chronic disease management, contributing to the nation’s vision of a healthier future through technology.
Comments